Literature DB >> 15793138

Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.

Milagros Corrales1, Rubén Cardozo, María Asunción Segura, Julio A Urbina, Miguel Angel Basombrío.   

Abstract

We carried out a comparative study of benznidazole and TAK-187, a long-lasting ergosterol biosynthesis inhibitor, with a murine model of Chagas' disease. The results indicated that TAK-187 was more effective than benznidazole in preventing Trypanosoma cruzi-induced cardiac damage in experimental animals.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793138      PMCID： PMC1068647          DOI： 10.1128/AAC.49.4.1556-1560.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Pathogenesis of chronic chagas heart disease: parasite persistence and autoimmune responses versus cardiac remodelling and neurohormonal activation.

Authors:  Diego F Dávila; Osman Rossell; Gabriela Arata de Bellabarba
Journal:  Int J Parasitol       Date:  2002-01       Impact factor: 3.981

Review 2.  A critical review on Chagas disease chemotherapy.

Authors:  José Rodriques Coura; Solange L de Castro
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-01       Impact factor: 2.743

Review 3.  Specific chemotherapy of Chagas disease: controversies and advances.

Authors:  Julio A Urbina; Roberto Docampo
Journal:  Trends Parasitol       Date:  2003-11

Review 4.  Chemotherapy of Chagas disease.

Authors:  Julio A Urbina
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

5.  Early electrocardiographic abnormalities in Trypanosoma cruzi-seropositive children.

Authors:  A L de Andrade; F Zicker; A Rassi; A G Rassi; R M Oliveira; S A Silva; S S de Andrade; C M Martelli
Journal:  Am J Trop Med Hyg       Date:  1998-10       Impact factor: 2.345

6.  Control of Chagas disease.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2002

7.  Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation.

Authors:  C Britto; M A Cardoso; C M Vanni; A Hasslocher-Moreno; S S Xavier; W Oelemann; A Santoro; C Pirmez; C M Morel; P Wincker
Journal:  Parasitology       Date:  1995-04       Impact factor: 3.234

8.  Cure of short- and long-term experimental Chagas' disease using D0870.

Authors:  J A Urbina; G Payares; J Molina; C Sanoja; A Liendo; K Lazardi; M M Piras; R Piras; N Perez; P Wincker; J F Ryley
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

9.  A simple protocol for the physical cleavage of Trypanosoma cruzi kinetoplast DNA present in blood samples and its use in polymerase chain reaction (PCR)-based diagnosis of chronic Chagas disease.

Authors:  C Britto; M A Cardoso; P Wincker; C M Morel
Journal:  Mem Inst Oswaldo Cruz       Date:  1993 Jan-Mar       Impact factor: 2.743

10.  Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains.

Authors:  Julio A Urbina; Gilberto Payares; Cristina Sanoja; Judith Molina; Renee Lira; Zigman Brener; Alvaro J Romanha
Journal:  Int J Antimicrob Agents       Date:  2003-01       Impact factor: 5.283
View more
  9 in total

1.  The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.

Authors:  Marcela L Ferraz; Ricardo T Gazzinelli; Rosana O Alves; Julio A Urbina; Alvaro J Romanha
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

Authors:  Frederick S Buckner; Julio A Urbina
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-12       Impact factor: 4.077

3.  Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.

Authors:  Carolina Davies; Rubén Marino Cardozo; Olga Sánchez Negrette; María Celia Mora; Man Chin Chung; Miguel Angel Basombrío
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

4.  Rational modification of a candidate cancer drug for use against Chagas disease.

Authors:  James M Kraus; Christophe L M J Verlinde; Mandana Karimi; Galina I Lepesheva; Michael H Gelb; Frederick S Buckner
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

5.  Modulation of autoimmunity by treatment of an infectious disease.

Authors:  Kenneth V Hyland; Juan S Leon; Melvin D Daniels; Nick Giafis; LaKitta M Woods; Thomas J Bahk; Kegiang Wang; David M Engman
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

6.  Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells.

Authors:  Robson Xavier Faria; Daniel Tadeu Gomes Gonzaga; Paulo Anastácio Furtado Pacheco; André Luis Almeida Souza; Vitor Francisco Ferreira; Fernando de Carvalho da Silva
Journal:  J Bioenerg Biomembr       Date:  2018-02-23       Impact factor: 2.945

Review 7.  Drug strategies targeting CYP51 in neglected tropical diseases.

Authors:  Jun Yong Choi; Larissa M Podust; William R Roush
Journal:  Chem Rev       Date:  2014-10-22       Impact factor: 60.622

Review 8.  Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase.

Authors:  Hugo Cerecetto; Mercedes González
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-25

Review 9.  Experimental and Clinical Treatment of Chagas Disease: A Review.

Authors:  Policarpo Ademar Sales Junior; Israel Molina; Silvane Maria Fonseca Murta; Adrián Sánchez-Montalvá; Fernando Salvador; Rodrigo Corrêa-Oliveira; Cláudia Martins Carneiro
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.